Most people think of the shingles vaccine as protection against shingles — the painful, blister-forming reactivation of the chickenpox virus that affects roughly one in three people over 50. That protection is real and substantial.
But a major new study suggests the vaccine is quietly doing something else as well. Something cardiologists are describing as remarkable.
The Numbers
Researchers led by Dr. Robert Nguyen at the University of California, Riverside, analysed data from more than 246,822 US adults aged 50 and older who all had pre-existing atherosclerotic heart disease — the most common form, caused by the build-up of plaques in arteries.
Among those who received a shingles vaccine, the findings were striking:
- 46% lower rate of major adverse cardiac events within one year
- 66% lower risk of death from any cause
- 32% lower risk of heart attack specifically
- 25% lower risk of stroke
- 25% lower risk of heart failure
The researchers note that the level of cardiac protection observed is comparable to the benefit of quitting smoking — one of the most powerful lifestyle interventions known to cardiology.
The study will be presented at the American College of Cardiology's Annual Scientific Session (ACC.26) on March 30, 2026.
Why Would a Shingles Vaccine Protect Your Heart?
The proposed mechanism involves clotting. The varicella-zoster virus — which causes both chickenpox and shingles — when reactivated, can trigger inflammatory responses and promote the formation of blood clots. In patients with already-compromised arteries, those clots can cause heart attacks and strokes.
By preventing shingles in the first place, the vaccine may be eliminating a dangerous source of clot-triggering inflammation before it starts. The effect is particularly significant in people with existing cardiovascular disease, precisely because their arteries are already more vulnerable to clot-related events.
An Underappreciated Vaccine
Shingles vaccination rates remain surprisingly low. In the United States, only about a third of eligible adults over 50 are vaccinated, despite the available Shingrix vaccine being both highly effective and widely recommended. Cost, lack of awareness, and general vaccine hesitancy are all factors.
These results add to a growing body of evidence that the shingles vaccine's benefits extend well beyond preventing a painful rash. Previous research has linked it to a reduced risk of dementia. Now comes evidence for substantial cardiovascular protection.
"If these results hold up in further research," said one cardiologist reviewing the findings, "the shingles vaccine could become a standard recommendation for cardiac risk reduction — not just for shingles prevention."
Sources: American College of Cardiology · ScienceDaily · CIDRAP · University of California Riverside, March 2026
